Our cutting-edge technology speaks the native language of cells, understanding at a microscopic level how cells grow and expand. Our platforms are then able to harness cells to develop the products and solutions of the future. Since 2003, we’ve been taking single placenta cells, growing them into billions of cells, and creating groundbreaking cell-based therapies to treat patients around the world. Due to their nature, these placental cells have no need for genetic matching – a huge advantage in cell therapy.

And because we never stopped listening to cells, we can innovate for the future. Today, we are using our cell expansion platforms to develop next generation products in pharmaceuticals, food technology, and beyond.

We’ve perfected the manufacturing processes necessary to grow cells efficiently in mass quantities. This led to the development of our innovative line of cell-based product candidates in regenerative medicine, a rich IP portfolio, ongoing Phase I to Phase III clinical studies, and the launch of a landmark joint venture with Tnuva Group to create cultivated food products in early 2022.